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studies have documented microbes in the channels of reprocessed gastrointestinal (GI) endoscopes,
including duodenoscopes and linear echoendoscopes. Our aim is to estimate the channel contamination rate of patient-ready reprocessed GI endoscopes based on the currently available data.
Methods: We searched PubMed, Web of Science, and Embase from January 1, 2010, until October
10, 2020, for studies investigating contamination rates of channels of patient-ready ﬂexible GI endoscopes by following the PRISMA guidelines. A random-eﬀects model based on the proportion
distribution was used to calculate pooled total contamination rate. A subgroup analysis was carried
out for studies originating from North America (USA and Canada). We used the meta-package
(metafor) in RStudio version 3.6.2 to conduct the statistical analyses. Heterogeneity between the
included studies was analyzed using the inconsistency index (I2) statistics. Publication bias was
assessed using funnel plots and Egger’s regression tests.
Results: We identiﬁed 1,230 peer-reviewed studies after duplicates were removed. Finally, 20 studies
fulﬁlled the inclusion criteria, including 1,059 positive cultures from 7,903 samples. The total
weighted contamination rate was 19.98% 6 0.024 (95% Cl: 15.29%-24.68%; I2598.6%) (ﬁgure 1a).
Subgroup analysis amongst studies from North America (n57) showed a contamination rate of
6.01% 6 0.011 (95% Cl: 3.88%-8.15%; I2589.3%) (ﬁgure 1b). I2 indicated high heterogeneity. Egger’s
regression test indicated no signiﬁcant publication bias for both groups (Egger’s test of publication
bias: p50.0531 and p50.0655).
Conclusion: Our analysis demonstrates that 19.98% of reprocessed patient-ready GI endoscopes
may be contaminated. The contamination rate was lower amongst US studies, which may be attributed to the actions taken in the US to overcome this issue. However, our ﬁndings highlight that
the elevator mechanism is not the only obstacle when reprocessing endoscopes. More studies are
needed to fully determine the role of contaminated endoscope channels in the cross-transmission
between the patients.
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Introduction: The elevator mechanism has been suggested as the main reason for multiple outbreaks
associated with contaminated reusable patient-ready duodenoscopes. The elevator is diﬃcult to clean
even with all precautions, and specially designed brushes are recommended for proper cleaning.
However, the narrow channels of the duodenoscope might pose a risk of contamination since they are
prone to scratches by the insertion of various accessories creating space for microbes to hide. Our aim
is to estimate the contamination rate beyond the elevator of duodenoscopes based on currently
available literature.
Methods: We searched PubMed, Web of Science, and Embase from January 1, 2010, until October
10, 2020, for studies investigating contamination rates of reprocessed duodenoscope channels and
areas beyond the elevator. A random-eﬀects model (REM) based on the proportion distribution was

[0992] Table 1. Study characteristics of included studies.

[0992] Figure 1. Pooled estimates of contamination rates beyond the elevator of patient-ready
duodenoscope. CI: confidence interval; prop: proportion.

used to calculate the pooled total contamination rate beyond the elevator of reprocessed duodenoscopes. The meta-package (metafor) in RStudio version 3.6.2 was used to conduct the statistical
analyses. Heterogeneity between the included studies was analyzed using the inconsistency index (I2)
statistics. Publication bias was assessed using the funnel plot and Egger’s regression test.
Results: Eight studies including 215 positive cultures from 2,001 samples fulﬁlled the inclusion
criteria. Four studies (50%) originated from the US, 3 studies (37.5%) originated from Europe (Italy,
Netherlands, and Austria), and 1 study (12.5%) was conducted in Taiwan. See table 1 for baseline
characteristics of the included studies. The total weighted contamination rate was 14.41% 6 0.029
(95% conﬁdence interval [Cl]: 8.70% - 20.13%), see ﬁgure 1. I2 was 96.4% indicating high heterogeneity. Egger’s regression test indicated no signiﬁcant publication bias (Egger’s test of publication
bias: p50.9919).
Conclusion: Our analysis indicates that 14.41% of reprocessed patient-ready duodenoscopes may be
contaminated unrelated to the elevator. These ﬁndings highlight that the elevator mechanism is not
the only part of the duodenoscope, which could remain contaminated even after reprocessing.
Despite the role of contaminated channels has been studied, more evidence is needed to fully
determine the consequences and potential link to patient-to-patient infections. Additionally, guidelines for disinfection units should recommend thorough surveillance of the endoscope channels to
minimize endoscope-related infections.
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Introduction: With the development of endoscopic technologies, the detection rate of early gastric
cancer (EGC) and precancerous lesions is gradually increasing. As an eﬀective minimally invasive
therapy, endoscopic submucosal dissection (ESD) has been accepted as a standard treatment for EGC
and dysplasia. However, postprocedural bleeding is one of the most common complications of ESD,
with a reported incidence of 5.1%. Moreover, the eﬀect of continued low-dose aspirin (LDA) on
bleeding during the peri-ESD period is not clear.
Methods: We searched the OVID/Medline and Google Scholar databases through June 2021 to ﬁnd
studies relating to continued LDA use in patients undergoing ESD. Studies reporting bleeding rates in
patients undergoing ESD with and without continued LDA were included. Postoperative bleeding
rates were compared between those who continued LDA during the procedure and those who did
not; a random-eﬀects model was used to calculate pooled odds ratio for bleeding risk with continued
LDA use. A p-value , 0.05 was considered statistically signiﬁcant.
Results: The initial search identiﬁed 2023 studies; after excluding duplicates, review articles, and
studies not meeting inclusion criteria, 9 studies (all were retrospective observational studies) were
ﬁnally included in the analysis. The total number of patients undergoing ESD procedure was 7978,
out of which 703 continued LDA during the procedure. Pooled analysis comparing the post-operative
bleeding rates between people with and without continued use of LDA revealed that aspirin use
during ESD translated into higher postoperative bleeding rates compared to those who did not.
(Pooled OR 1.720 , 95%CI: 1.121-2.641, P5 0.01). No interstudy heterogeneity was observed (I250).

[0993] Figure 1. Forest plot of gastric neoplasm studies with and without continuation of lowdose aspirin.
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[0993] Table 1. Baseline Characteristics of Included Studies.

[0994] Table 1. Product Recalls for Duodenoscopes and Accessories.

Conclusion: The results of our meta-analysis demonstrated that LDA continuation signiﬁcantly
increased the risk of post-ESD bleeding. Therefore, the physicians should individualize the decision of
continuing LDA in patients undergoing ESD based on their thrombotic risk.
S994
Medical Device Safety in Gastroenterology: FDA Recalls of Duodenoscopes, 2015-2020
Rushi K. Talati, MD1, Adam Goodman, MD2, Mark B. Pochapin, MD1.
1
2
New York University School of Medicine, New York, NY; New York University Langone Medical
Center, New York, NY.
Introduction: Duodenoscopes are used in more than 500,000 procedures annually in the US as a
minimally invasive diagnostic and therapeutic modality for hepatobiliary and pancreatic diseases.
Traditionally, these devices have been intended for re-use after undergoing strict cleaning and disinfection protocols to reduce the risk of infection between patients. However, since 2008, several
major outbreaks of infections linked to duodenoscopes have resulted in devices recalled from the
market. Understanding what occurred in instances of device failure leading to recalls is important to
improve the safety and eﬃcacy of these devices.
Methods: This institution review board-exempt study reviewed the FDA Center for Devices and
Radiologic Health database for all duodenoscope-related recall events from November 1, 2002
through December 31, 2020. Market entry data, recall characteristics, and adverse reports were
collected for each device.
Results: Seventeen class II duodenoscope-related recall events were identiﬁed, aﬀecting at least
24,611 units in distribution. 12 out of the 17 (70%) recall events were for duodenoscopes, 3 out of 17
(18%) recalls were for operation manuals, and 2 out of 17 (12%) recalls were for reprocessors. 15 out
of 17 recalled devices (88%) had at least 1 documented occurrence of an adverse event at the time of
recall. All recall events were approved via the 510k pathway, however postmarket-related issues
accounted for 88% of recalls.
Conclusion: Given the wide utilization of duodenoscopes in treating pancreaticobiliary diseases, an
understanding of their recall events and associated public health impact are important for endoscopists to have a greater awareness of potential safety concerns. Recalls by three duodenoscope
manufacturers and one scope reprocessor manufacturer highlight the need for innovation in design
and improved post-marketing surveillance mechanisms.
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Endoscopic Ultrasound-Guided Celiac Plexus Block for Pain Relief in Chronic Pancreatitis Is an
Eﬀective Procedure When Used Judiciously
Nikhil Sonthalia, MD, DM, Mahesh K. Goenka, MD, DM, FACG, Vikram Patil, MD,
Bhavik Shah, MD, Shivaraj Afzalpulkar, MD.
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Introduction: There is not enough data available for the eﬀectiveness of Endoscopic ultrasound guided celiac plexus block (EUS-CPB) for pain relief in chronic pancreatitis (CP) among
Indian patients where the aetiology and phenotype of CP are diﬀerent from the western
population. The aim of the current study was to ﬁnd out the eﬃcacy of EUS-CPB in CP
irrespective of whether the patients have undergone Endoscopic Retrograde Cholangiopancreatography (ERCP) or not.
Methods: A prospectively maintained data base of patients undergoing EUS-CPB was analyzed.
EUS-CPB was done by injecting mixture of 0.25% bupivacaine and triamcinolone acetate as per the

The American Journal of GASTROENTEROLOGY

institutional protocol. Both central and bilateral techniques were used depending upon the
feasibility. The main outcome measures were, 1) response to Celiac plexus block which was
deﬁned as more then 50% reduction in visual analogue scale (VAS) pain score after the
procedure, 2) VAS pain score recorded at 4,12, 24 weeks after the procedure, 3) adverse event
attributed to the procedure and 4) duration of response. In addition, factors among responders
and non-responders were compared.
Results: In total 22 patients of CP underwent EUS-CPB between 2018 and 2021 for refractory pain
.The mean age of patients was 40.2 years, among which males were 63.6%. Disease duration was
classiﬁed as Short duration (# 2 years) of CP which was seen in 36.4 % and long duration ( .2 years)
of CP which was seen in 63.6 %. Overall 18/22 (81.8 %) patients had response to EUS-CPB . Among
responders, mean duration of response was 8 months (Standard deviation-4.73). Mean VAS score at
4,12 weeks and 24 weeks after procedure were signiﬁcantly lower among those who had short
duration of CP as compared to those with longer duration (Figure 1). Males had signiﬁcantly better
response as compared to females (100% vs 50%, p-0.01 ). Among responders signiﬁcant proportion of
patients discontinued the use of pain killer or used them occasionally. There was no signiﬁcant
diﬀerence in response to EUS-CPB according to the ERCP status of the patients. Total ﬁve adverse
events- hypotension in 3 and diarrhoea in 2 patients were encountered. No major or serious adverse
events occurred.
Conclusion: In our population, EUS-CPB is a safe and eﬀective procedure in select group of
chronic pancreatitis patients when used judiciously. Males had better response than females in
our study. EUS-CPB may have a better result when used early in course of CP irrespective of
ERCP status.
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